A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

NCT03059615 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No recruitment since initiation

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Nerofe
DRUG: Doxorubicin

Sponsor

Immune System Key Ltd